三氟甲吡醚 | 179101-81-6

• 物质功能分类: 化学农药原药 - 杀虫剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 三氟甲吡醚
• 中文别名: 2-[3-[2,6-二氯-4-[(3,3-二氯-2-丙烯-1-基)氧基]苯氧基]丙氧基]-5-(三氟甲基)吡啶；2-[3-[2,6-二氯-4-[(3,3-二氯-2-丙烯基)氧基]苯氧基]丙氧基]-5-(三氟甲基)嘧啶；啶虫丙醚
• 英文名称: pyridalyl
• 英文别名: 3,5-dichloro-1-(3,3-dichloro-2-propenyloxy)-4-[3-(5-trifluoromethylpyridine-2-yloxy)-propoxy]-benzene；2-(3-{2,6-dichloro-4-[(3,3-dichloroprop-2-en-1-yl)oxy]phenoxy}propoxy)-5-(trifluoromethyl)pyridine；2-[3-[2,6-dichloro-4-[(3,3-dichloro-2-propenyl)oxy]phenoxy]propoxy]-5-(trifluoromethyl)pyrimidine；2-[3-[2,6-dichloro-4-[(3,3-dichloro-2-propenyl)oxy]phenoxy]propoxy]-5-(trifluoromethyl)-pyridine；2-[3-[2,6-dichloro-4-[(3,3-dichloro-2-propenyl)oxy]phenoxy]propoxy]-5-(trifluoromethyl)pyridine；2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-[5-(trifluoromethyl)-2-pyridyloxy]propyl ether；2-[3-[2,6-dichloro-4-(3,3-dichloroprop-2-enoxy)phenoxy]propoxy]-5-(trifluoromethyl)pyridine
• CAS: 179101-81-6
• 化学式: C₁₈H₁₄Cl₄F₃NO₃
• 分子量: 491.121
• InChiKey: AEHJMNVBLRLZKK-UHFFFAOYSA-N

物化性质

• 沸点：
  545.4±50.0 °C(Predicted)
• 密度：
  1.450
• 颜色/状态：
  Liquid
• 溶解度：
  In water, 150 mg/L at 20 °C
• 蒸汽压力：
  6.24X10-5 mPa /SRC: 4.68X10-10 mm Hg/ at 20 °C

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  7

ADMET

代谢

每组3只Sprague-Dawley（Crl:CDBR）大鼠/性别/组，灌胃给予高纯度的吡啶醛，其中加入了至少97%纯度的标记吡啶醛（苯基或丙烯基标记的），以达到5或500 mg/kg的单次灌胃剂量，每只大鼠50:Ci。该研究评估了在4个时间点（基于记录号242040的结果）许多组织中采集的放射性：1/2 Cmax（吸收），Cmax，1/2 Cmax（消除），和1/10 Cmax（消除）。这些采样时间分别是5 mg/kg苯基标记的4、8、24和48小时，500 mg/kg苯基标记的6、8、24和48小时，5 mg/kg丙烯基标记的4、12、48和120小时，以及500 mg/kg丙烯基标记的6、12、72和120小时。评估了五个组织中可提取残留物：肝脏、肾脏、肺、血液和脂肪。在这些组织中评估了主要代谢物。肝脏中1/10 Cmax的主要代谢物是二氯丙烯基降解产物，产生相应的苯氧乙酸（命名为S-1812-PhCH2COOH）。 ... 肝脏中1/10 Cmax的主要代谢物是二氯丙烯基降解产物，产生相应的苯氧乙酸（命名为S-1812-PhCH2COOH）。这种相同的酸通常是血液中的主要成分，特别是在消除阶段。血液还携带大量和可变的未定性极性成分。在苯基标记实验中，还有一个较重要的已鉴定代谢物：S-1812-DP（失去二氯丙烯基产生一个酚）。S-1812-DP偶尔构成超过20%的提取放射性标记，并且没有强烈倾向于任何一个组织。另一个相对较小的已鉴定代谢物是HPHM[失去三氟吡啶基，其余母体不变]。HPHM很少超过提取放射性标记的几个百分点，通常低于检测限。在丙烯基取代基中标记位置导致了在高度极性组分中回收标记的百分比增加。

Groups of 3 Sprague-Dawley (Crl:CDBR) rats/sex/group were dosed with pyridalyl of high purity, to which labeled pyridalyl (either phenyl or propenyl-labeled) pyridalyl of at least 97% purity was added to achieve 5 or 500 mg/kg single gavage doses at 50:Ci/rat. The study evaluated radioactivity in many tissues sampled at 4 times (based on results of Record No. 242040): 1/2 Cmax (absorption), Cmax, 1/2 Cmax (elimination), and 1/10 Cmax (elimination). These sampling times were 4, 8, 24, and 48 hrs for 5 mg/kg phenyl label, 6, 8, 24, and 48 hrs for 500 mg/kg phenyl label, 4, 12, 48, and 120 hrs for 5 mg/kg propenyl label, and 6, 12, 72, and 120 hrs for 500 mg/kg propenyl label. Five tissues were evaluated for extractable residues: liver, kidney, lung, blood, and fat. Major metabolites were evaluated in these tissues. The major metabolite in liver by 1/10 Cmax was the product of degradation of the dichloropropenyl group to yield the corresponding phenoxyacetic acid (designated S-1812-PhCH2COOH). ... The major metabolite in liver by 1/10 Cmax was the product of degradation of the dichloropropenyl group to yield the corresponding phenoxyacetic acid (designated S-1812-PhCH2COOH). This same acid was typically a major component of blood, particularly in the elimination phase. Blood also carried large and variable amounts of uncharacterized polar components. One more characterized metabolite was relatively important in phenyl labeling experiments: S-1812-DP (loss of the dichloropropenyl group to yield a phenol). S-1812-DP occasionally constituted over 20% of extracted radiolabel, and had no strong proclivity for any one tissue. A comparatively minor characterized metabolite was HPHM [loss of the trifluoropyridine group, with the balance of parent unchanged]. HPHM rarely exceeded a few percent of extractable radiolabel, and often was below detection limits. Label placement in the propenyl substituent led to increased percent of recovered label in the highly polar fraction.

来源:Hazardous Substances Data Bank (HSDB)

代谢

Sprague-Dawley (Crl:CDBR) 大鼠按性别分为每组4只，通过灌胃给予玉米油载体的单次给药。设置了低剂量和高剂量组，分别为5 mg/kg/天和500 mg/kg/天，其中14C标记位于苯基和丙烯基团上，而吡啶基团上的标记仅设置为5 mg/kg/天。研究者评估了排泄物中的代谢物，并量化了随时间排出的CO2。在168小时后检查了组织的放射性。大约90%的苯基或吡啶基标记的吡啶醇放射性在粪便中被回收，其中大约2%在尿液中，剩余的放射性在组织（大约1%）和尸体（高达4%）中被发现。没有显著的剂量效应。从苯基或吡啶基标记的物质中没有获得CO2。相比之下，丙烯基标记导致11-12%的放射性以CO2形式在呼出气体中被回收，除此之外，还有55-59%的标记在粪便中，10-18%在尿液中，2%在组织中，以及4-8%在尸体中。排泄产物的分析没有表明性别在分布上的差异，然而，吡啶醇的代谢程度通常在较高剂量水平上有所减少。低剂量暴露于苯基或吡啶基标记导致31-39%的给药标记以母体吡啶醇形式存在，42-51%的标记为S-1812-DP（失去二氯丙烯基团产生一个酚），大约2%的标记为S-1812-Py-OH（羟基取代基添加到吡啶环上），以及高达4-7%的给药剂量为HPHM（失去吡啶环：在低剂量苯基标记的情况下相关）。高剂量暴露于苯基标记导致约50%的给药标记以母体吡啶醇形式存在，而仅有25-29%的标记为S-1812-DP。在吡啶基标记给药后，吡啶环的断裂产生了2-羟基-5-三氟甲基吡啶（HTFP）或3-羟基-5-三氟甲基吡啶酮（HPDO）的共轭产物：每一种后者约占给药剂量的1%。丙烯基标记给药后的尿液含有许多极性产物，但没有一种是丰富的。无论标记位置如何，大部分排泄的放射性都是在给药后前48小时内获得的。

Groups of 4 Sprague-Dawley (Crl:CDBR) rats/sex were dosed once by gavage in corn oil vehicle. There were low-dose and high dose groups at 5 and 500 mg/kg/day, respectively, with 14C label placement in phenyl and propenyl groups, and 5 mg/kg/day only for label placement in the pyridyl group. Investigators evaluated excreta for metabolites, and quantified expired CO2 over time. Tissues were examined for radioactivity after 168 hrs. About 90% of recovered radioactivity following phenyl- or pyridyl-labeled pyridalyl was found in feces, with about 2% in urine, and the balance of recovered radioactivity was found in tissues (about 1%), and carcass (up to 4%). There was no remarkable dose effect. No CO2 was obtained from phenyl- or pyridyl-labeled material. In contrast, propenyl-label led to 11-12% in expired air as CO2, in addition to 55-59% of label in feces, 10-18% in urine, 2% in tissues, and 4-8% in carcass. Analyses of excreted products did not indicate sex differences in disposition, however the extent of metabolism of pyridalyl was typically reduced at the higher dose levels. Low dose exposure to either phenyl or pyridyl label led to 31-39% of administered label in parent pyridalyl, 42-51% of label as S-1812-DP (loss of the dichloropropenyl group to yield a phenol), about 2% of label as S-1812-Py-OH (hydroxy substituent added to pyridyl ring), and up to 4-7% of administered dose as HPHM (loss of the pyridyl ring: relevant in the case of low dose phenyl-label). High dose exposure to phenyl label led to about 50% of administered label as parent pyridalyl and only 25-29% of label as S-1812-DP. Cleavage of the pyridyl ring after pyridyl-label administration yielded 2-hydroxy-5-trifluoromethylpyridine (HTFP) or conjugation products of 3-hydroxy-5-trifluoromethylpyridone (HPDO): each of the latter comprising about 1% of administered dose. Urine following administration of propenyl label consisted of many polar products, none of which was abundant. The majority of excreted radioactivity was obtained within the first 48 hrs after dosing, regardless of label position.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 立即急救：确保已经进行了充分的中和。如果患者停止呼吸，请开始人工呼吸，最好使用需求阀复苏器、球囊阀面罩设备或口袋面罩，按训练操作。如有必要，执行心肺复苏。立即用缓慢流动的水冲洗受污染的眼睛。不要催吐。如果患者呕吐，让患者身体前倾或将其置于左侧（如果可能，头部向下）以保持呼吸道畅通，防止吸入。保持患者安静，维持正常体温。寻求医疗救助。 /毒物A和B/

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 基本治疗：建立专利气道（如有需要，使用口咽或鼻咽气道）。如有必要，进行吸痰。观察呼吸不足的迹象，如有需要，辅助通气。通过非循环呼吸面罩以10至15升/分钟的速度给予氧气。监测肺水肿，如有必要，进行治疗……。监测休克，如有必要，进行治疗……。预防癫痫发作，如有必要，进行治疗……。对于眼睛污染，立即用水冲洗眼睛。在运输过程中，用0.9%的生理盐水（NS）持续冲洗每只眼睛……。不要使用催吐剂。对于摄入，如果患者能吞咽、有强烈的干呕反射且不流口水，则用温水冲洗口腔，并给予5毫升/千克，最多200毫升的水进行稀释……。在去污后，用干燥的无菌敷料覆盖皮肤烧伤……。/毒药A和B/

/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 高级治疗：对于无意识、严重肺水肿或严重呼吸困难的病人，考虑进行口咽或鼻咽气管插管以控制气道。使用气囊面罩装置的正压通气技术可能有益。考虑使用药物治疗肺水肿……。对于严重的支气管痉挛，考虑给予β激动剂，如沙丁胺醇……。监测心率和必要时治疗心律失常……。开始静脉输注D5W /SRP: "保持开放"，最低流量/。如果出现低血容量的迹象，使用0.9%生理盐水（NS）或乳酸林格氏液。对于伴有低血容量迹象的低血压，谨慎给予液体。注意液体过载的迹象……。使用地西泮或劳拉西泮治疗癫痫……。使用丙美卡因氢氯化物协助眼部冲洗……。 /Poisons A and B/

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

实验动物：亚慢性或前慢性暴露/每组6只雄性Crj:CD（SD）大鼠接受0或7000 ppm的S-1812技术（批号：TH95030701，纯度：95.1%）饲料喂养2周（0，603 mg/kg/天）。没有因处理导致的死亡。处理期间，处理组动物的平均体重低于对照组（p<0.01或0.05）。7000 ppm组的食物消耗量显著低于对照组（p<0.01）。7000 ppm组动物的平均红细胞计数、血红蛋白浓度和血细胞比容较对照组升高（p<0.01）。网织红细胞计数低于对照组（p<0.01）。7000 ppm组动物的凝血酶原和活化部分凝血活酶时间延长（p<0.01）。在临床化学评估中，7000 ppm组动物的总血清胆固醇、甘油三酯、磷脂和血尿素氮升高（p<0.01或0.05）。7000 ppm组动物血清中的丙氨酸转氨酶活性增加（p<0.01）。无机磷酸盐水平高于对照组（p<0.01）。与对照组相比，这些动物的血清钾水平降低（p<0.05）。7000 ppm组动物的平均相对肝脏、睾丸和肾上腺重量大于对照组（p<0.01或0.05）。7000 ppm组动物的肝脏外观呈暗色。在7000 ppm组肺部的组织病理学检查中，有3只动物出现水肿。3只动物出现中膜动脉增厚。所有动物的肺泡中均可见到泡沫状嗜酸性粒细胞。

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Six male Crj:CD (SD) rats/group received 0 or 7000 ppm of S-1812 Technical (lot no. TH95030701, purity: 95.1%) in the diet for 2 weeks (0, 603 mg/kg/day). No deaths resulted from the treatment. The mean body weight of the treated animals was less than that of the control group throughout the treatment period (p<0.01 or 0.05). The food consumption by the 7000 ppm animals was significantly less than that of the control group (p<0.01). The mean red blood cell count, hemoglobin concentration and hematocrit of the 7000 ppm animals were elevated in comparison to the control animals (p<0.01). The reticulocyte count was lower than that of the control group (p<0.01). The prothrombin and activated partial thromboplastin times were prolonged for the 7000 ppm animals (p<0.01). In the clinical chemistry evaluation, the total serum cholesterol, triglycerides, phospholipids and blood urea nitrogen were elevated for the 7000 ppm animals (p<0.01 or 0.05). Alanine aminotransferase activity in the serum of the 7000 ppm animals was increased (p<0.01). The inorganic phosphate level was greater than the control value (p<0.01). The serum potassium level was reduced for these animals in comparison to the control group (p<0.05). The mean relative liver, testes and adrenal weights were greater for the 7000 ppm animals than the control group (p<0.01 or 0.05). The livers of the 7000 ppm animals were dark in appearance. In the histopathological examination of the lungs of the 7000 ppm group, edema was noted for three of the animals. Medial arterial thickening was noted for 3 of these animals. Foamy, eosinophilic cells were noted in the alveoli of all of the animals.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

实验动物：亚慢性或预慢性暴露/每组6只Crj:CD(SD)大鼠/性别，接受0、70、200、700或2000 ppm的S-1812技术产品（批号：NSA-950525，纯度：98.7%）饮食，持续4周（报告的活性成分摄取量：(雄性)0、7.05、19.5、64.6、182 mg/kg/天，(雌性)0、7.21、19.6、66.4、188 mg/kg/天）。另外一组每组6只大鼠/性别接受了0或2000 ppm的测试物质饮食，持续2周。治疗没有导致死亡。2000 ppm组雄性的平均体重低于对照组动物（p<0.01或0.05）。700和2000 ppm雄性在研究的前2周的食物消耗量低于对照组（p<0.01）。对于2000 ppm的动物来说，这种效果一直持续到研究结束。尿检或血液学检查中没有出现与治疗相关的影响。在临床化学评估中，两个性别的2000 ppm组在治疗2周后总胆固醇和磷脂水平升高（p<0.01或0.05）。治疗4周后，700和2000 ppm雄性的总胆固醇水平与对照组相比统计学上显著升高（p<0.01或0.05）。700和2000 ppm组两个性别的相对平均肝重量以及200 ppm雌性在治疗4周后大于对照组（p<0.01或0.05）。2000 ppm组两个性别的相对平均肺重量大于对照组（p<0.01或0.05）。2000 ppm雌性的平均绝对和相对卵巢重量大于对照组（p<0.01）。在组织病理学检查中，2000 ppm雄性在治疗2周后和雌性在治疗2周和4周后肾上腺皮质的退化和/或空泡化被注意到。在2000 ppm雌性的卵巢中，在治疗2周和4周后也注意到了间质细胞的退化和/或空泡化。在两个时间点，持续存在的黄体也被观察到。在电子显微镜下检查的组织样本中，在治疗2周后，2000 ppm组的一只雄性和两只雌性肾上腺网状带中略微增加了脂肪空泡化。治疗4周后，网状带中也注意到了空泡化，这只雄性和两只雌性。网状带的线粒体轻微肿胀也清楚地出现在这两只雌性中。可能的不良影响：肾上腺皮质和卵巢间质细胞的退化；大鼠四周饮食NOEL：(雄性/雌性)200 ppm（(雄性)19.5 mg/kg/天，(雌性)19.6 mg/kg/天）（基于700 ppm组两个性别较低的食量）。

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Six Crj:CD(SD) rats/sex/group received 0, 70, 200, 700 or 2000 ppm of S-1812 Technical (lot no. NSA-950525, purity: 98.7%) in the diet for 4 weeks (reported a.i. uptake: (M) 0, 7.05, 19.5, 64.6, 182 mg/kg/day, (F) 0, 7.21, 19.6, 66.4, 188 mg/kg/day). An additional group of 6 rats/sex/group received 0 or 2000 ppm of the test material in the diet for 2 weeks. No deaths resulted from the treatment. The mean body weights of the males in the 2000 ppm group were less than those of the control animals (p<0.01 or 0.05). The mean food consumption of the 700 and 2000 ppm males was less than the control values during the 1st 2 weeks of the study (p<0.01). This effect persisted to the termination of the study for the 2000 ppm animals. No treatment-related effects were apparent in the urinalysis or hematology. In the clinical chemistry evaluation, total cholesterol and phospholipid levels were elevated for both sexes in the 2000 ppm groups after two weeks of treatment (p<0.01 or 0.05). After 4-weeks of treatment, the total cholesterol level of the 700 and 2000 ppm males was statistically elevated above that of the control group (p<0.01 or 0.05). The relative mean liver weights for both sexes in the 700 and 2000 ppm groups and the 200 ppm females were greater than the control group after 4 weeks of treatment (p<0.01 or 0.05). The relative mean lung weights of both sexes in the 2000 ppm group were greater than those of the control group (p<0.01 or 0.05). The mean absolute and relative ovarian weights of the 2000 ppm females were greater than the control values (p<0.01). In the histopathology examination, degeneration and/or vacuolation of the adrenal cortex was noted in the 2000 ppm males after 2 weeks of treatment and in the 2000 ppm females after both 2 and 4 weeks of treatment. In the ovaries of the 2000 ppm females, degeneration and/or vacuolation of the interstitial cells was noted after both 2 and 4 weeks of treatment. Persistent corpora luteum were also observed in the group at both time points. In the tissue samples examined by electron microscopy, slightly increased fatty vacuolation in the zona reticularis of the adrenal glands from one male and two females of the 2000 ppm group was observed after 2 weeks of treatment. After 4 weeks of treatment, vacuolation was also noted in the zona reticularis of one male and two females of the 2000 ppm group. Slight swelling of the mitochondria in the zone reticularis was evident for these two females as well. Possible adverse effect: degeneration of adrenal cortex and interstitial cells in the ovaries; Rat Four-Week Dietary NOEL: (M/F) 200 ppm ((M) 19.5 mg/kg/day, (F) 19.6 mg/kg/day) (based upon the lower food consumption noted for both sexes in the 700 ppm group).

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

将高纯度的吡噻菌胺以3只/性别/组的Sprague-Dawley (Crl:CDBR)大鼠进行给药，向其中添加至少97%纯度的标记吡噻菌胺（苯基或丙烯基标记），以达到5或500 mg/kg的单次灌胃剂量，每只大鼠50微居里。该研究评估了在4个时间点（基于记录编号242040的结果）采集的许多组织中的放射性：1/2 Cmax（吸收）、Cmax、1/2 Cmax（消除）和1/10 Cmax（消除）。对于5 mg/kg苯基标记，这些采样时间分别为4、8、24和48小时；对于500 mg/kg苯基标记，分别为6、8、24和48小时；对于5 mg/kg丙烯基标记，分别为4、12、48和120小时；对于500 mg/kg丙烯基标记，分别为6、12、72和120小时。评估了五种组织中可提取残留物：肝脏、肾脏、肺、血液和脂肪。在这些组织中评估了主要代谢物。全血标记按预期降低了一个数量级，在低剂量雄性和雌性大鼠给予苯基标记的情况下，从Cmax降至1/10 Cmax（消除），在低剂量雄性大鼠给予丙烯基标记的情况下也是如此。在其他情况下，1/10 Cmax（消除）的估计似乎过早。标记在脂肪中的持续时间最长（无论性别、剂量或标记位置如何）：在估计的1/10 Cmax（消除）时，常常显示出比Cmax更高的浓度。通常，在消除阶段，肾上腺的放射性标记高于除脂肪外的其他组织。其他一些组织，如甲状腺、胰腺和卵巢，在消除阶段常常比大多数其他组织具有更高的放射性标记含量，但差异通常很小且多变。在评估可提取残留物的五种组织中，脂肪的独特之处在于标记始终具有高度可提取性，并且几乎全部由母体吡噻菌胺组成，无论性别、剂量或标记位置如何。最初[1/2 Cmax（吸收）]，在给予苯基标记处理后，五个评估组织中超过91%的标记是可提取的。对于低剂量苯基组，在1/10 Cmax（消除）时，除脂肪外的其他组织的提取率从69%上升，各组织之间没有明显的差异。高剂量苯基组在1/10 Cmax（消除）时的提取率通常超过90%。丙烯基标记在1/2 Cmax（吸收）时的提取率范围为74%至95%，但随着时间的推移，所有组织的提取率都有所下降，因此在1/10 Cmax（消除）时的提取率为肝脏和肾脏37%至53%，肺53-67%，但血液非常低（低剂量丙烯基组提取率为21-22%，高剂量丙烯基组恒定为0%）。在苯基标记试验物品的早期吸收过程中，母体吡噻菌胺是肝脏、肾脏、肺、血液和脂肪中残留物的主要成分。在消除过程中，吡噻菌胺标记的百分比变化很大。在1/10 Cmax时，肝脏仅保留少量吡噻菌胺（不到10%的放射性标记），而此时脂肪仍含有95-100%的放射性标记作为吡噻菌胺。母体吡噻菌胺通常是肺和肾脏在1/10 Cmax时的主要成分。

Groups of 3 Sprague-Dawley (Crl:CDBR) rats/sex/group were dosed with pyridalyl of high purity, to which labeled pyridalyl (either phenyl or propenyl-labeled) pyridalyl of at least 97% purity was added to achieve 5 or 500 mg/kg single gavage doses at 50 uCi/rat. The study evaluated radioactivity in many tissues sampled at 4 times (based on results of Record No. 242040): 1/2 Cmax (absorption), Cmax, 1/2 Cmax (elimination), and 1/10 Cmax (elimination). These sampling times were 4, 8, 24, and 48 hrs for 5 mg/kg phenyl label, 6, 8, 24, and 48 hrs for 500 mg/kg phenyl label, 4, 12, 48, and 120 hrs for 5 mg/kg propenyl label, and 6, 12, 72, and 120 hrs for 500 mg/kg propenyl label. Five tissues were evaluated for extractable residues: liver, kidney, lung, blood, and fat. Major metabolites were evaluated in these tissues. Whole blood label diminished an order of magnitude as expected, from Cmax to 1/10 Cmax (elimination) in the case of low dose males and females administered phenyl label, and in low dose males administered the propenyl label. In other cases, it appeared that the estimate of 1/10 Cmax (elimination) was premature. Label persisted longest in fat (regardless of gender, dose, or label position): often showing a higher concentration at estimated 1/10 Cmax (elimination) than at Cmax. In general, adrenal radiolabel was higher than in tissues other than fat during the elimination phase. Some other tissues, such as thyroids, pancreas, and ovaries, often had radiolabel content higher than most other tissues during elimination phase, but differences were typically small and variable. Of the five tissues evaluated for extractable residues, fat was unique in that label was consistently highly extractable, and composed nearly all of parent pyridalyl, regardless of gender, dose, or label placement. Initially [1/2 Cmax (absorption)], over 91% of label in each of the 5 assessed tissues was extractable following phenyl-label treatment. Extractability for low-dose phenyl groups at 1/10 Cmax (elimination) for tissues other than fat ranged from 69% upward without obvious differences between tissues. Percent extractability for high-dose phenyl groups at 1/10 Cmax (elimination) was generally over 90%. Percent extractability of propenyl label at 1/2 Cmax (absorption) ranged from 74% to 95%, but dropped for all tissues over time, so that extractability at 1/10 Cmax (elimination) was 37% to 53% for liver and kidney, 53-67% for lung, but very low for blood (21-22% extractable for low dose propenyl groups, and a constant 0% for high dose propenyl groups). Parent pyridalyl was the major component of residues in liver, kidney, lung, blood, and fat during the early absorption process of phenyl-labeled test article. The percentage of pyridalyl label during elimination varied greatly. Liver retained only small amounts of pyridalyl at 1/10 Cmax (less than 10% of radiolabel), whereas fat still contained 95- 100% of radiolabel as pyridalyl at that time. Parent pyridalyl was typically the dominant component of lung and kidney through 1/10 Cmax.

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• WGK Germany：
  3
• 储存条件：
  保存方法：0至-6°C

制备方法与用途

概述

啶虫丙醚又叫三氟甲吡醚，是由日本住友化学工业株式会社于1997年创制的二氯丙烯醚类杀虫剂。这是一种新型高效、低毒的杀虫剂。

性质

啶虫丙醚是一种油状液体。它没有光学异构体，不存在顺反异构体，仅包含一个“流行”的三氟甲基吡啶基团。尽管其结构新颖，但并不复杂。

制备

制备啶虫丙醚的过程包括以下步骤：首先，对苯二酚与1,1,3-三氯丙烯反应生成4-(3,3-二氯烯丙氧基)苯酚；接着进行氯化和醚化反应，得到3-[2,6-二氯-4-(3,3-二氯烯丙氧基)苯氧基]丙-1-醇；最后与2-氯-5-三氟甲基吡啶反应，即可获得目的产物啶虫丙醚。

反应信息

• 作为产物：
  描述：

  3,5-dichloro-4-(3-(5-trifluoromethyl-2-pyridyloxy)propoxy)phenol 、 1,1,3-三氯丙烯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以47%的产率得到三氟甲吡醚
  参考文献：
  名称：

  Dihalopropene compounds, insecticidal/acaricidal agents containing same,

  摘要：

  通式为\x9bI!的二卤代丙烯化合物具有优异的杀虫/杀螨活性，因此它们对于控制有害昆虫、螨和蜱是相当有效的。

  公开号：

  US05922880A1

文献信息

• [EN] ACC INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'ACC ET UTILISATIONS ASSOCIÉES
  申请人：GILEAD APOLLO LLC

  公开号：WO2017075056A1

  公开（公告）日：2017-05-04

  The present invention provides compounds I and II useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.

  本发明提供了化合物I和II，这些化合物可用作乙酰辅酶A羧化酶（ACC）的抑制剂，以及它们的组合物和使用方法。
• [EN] BICYCLYL-SUBSTITUTED ISOTHIAZOLINE COMPOUNDS<br/>[FR] COMPOSÉS ISOTHIAZOLINE SUBSTITUÉS PAR UN BICYCLYLE
  申请人：BASF SE

  公开号：WO2014206910A1

  公开（公告）日：2014-12-31

  The present invention relates to bicyclyl-substituted isothiazoline compounds of formula (I) wherein the variables are as defined in the claims and description. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.

  本发明涉及公式（I）中变量如索权和说明中所定义的自行车基取代异噻唑啉化合物。这些化合物对抗或控制无脊椎动物害虫，特别是节肢动物害虫和线虫方面具有用途。该发明还涉及一种通过使用这些化合物来控制无脊椎动物害虫的方法，以及包含所述化合物的植物繁殖材料、农业和兽医组合物。
• [EN] AZOLINE COMPOUNDS<br/>[FR] COMPOSÉS AZOLINE
  申请人：BASF SE

  公开号：WO2015128358A1

  公开（公告）日：2015-09-03

  The present invention relates to azoline compounds of formula (I) wherein A, B1, B2, B3, G1, G2, X1, R1, R3a, R3b, Rg1 and Rg2 are as defined in the claims and the description. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.

  本发明涉及式（I）的噁唑啉化合物，其中A、B1、B2、B3、G1、G2、X1、R1、R3a、R3b、Rg1和Rg2如权利要求和描述中所定义。这些化合物对抗或控制无脊椎动物害虫，特别是节肢动物害虫和线虫方面具有用途。该发明还涉及一种利用这些化合物控制无脊椎动物害虫的方法，以及包括所述化合物的植物繁殖材料、农业和兽医组合物。
• [EN] MICROBIOCIDAL OXADIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXADIAZOLE MICROBIOCIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2017157962A1

  公开（公告）日：2017-09-21

  Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially fungicides.

  式(I)的化合物，其中取代基如权利要求1所定义，作为杀虫剂特别是杀菌剂有用。
• Thieno-pyrimidine compounds having fungicidal activity
  申请人：Brewster Kirkland William

  公开号：US20070093498A1

  公开（公告）日：2007-04-26

  The present invention relates to thieno[2,3-d]-pyrimidine compounds having fungicidal activity.

  本发明涉及具有杀真菌活性的噻吩[2,3-d]-嘧啶化合物。